AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

The dermatology market in the U.S. is at a pivotal moment of transformation, with spending poised to climb from $40.55 billion in 2023 to $70 billion by 2030. This unprecedented growth mirrors past ...

In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh ... Every breakthrough in medicine, every new treatment that changes lives, starts with research.